CS241062B2 - Method of anti-inflammation agent production for local application - Google Patents
Method of anti-inflammation agent production for local application Download PDFInfo
- Publication number
- CS241062B2 CS241062B2 CS835282A CS528283A CS241062B2 CS 241062 B2 CS241062 B2 CS 241062B2 CS 835282 A CS835282 A CS 835282A CS 528283 A CS528283 A CS 528283A CS 241062 B2 CS241062 B2 CS 241062B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- piroxicam
- composition
- carbon atoms
- gel
- skin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 239000002260 anti-inflammatory agent Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 claims abstract description 58
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229960002702 piroxicam Drugs 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 9
- 238000011200 topical administration Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- -1 alkylene glycol Chemical compound 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 231100000245 skin permeability Toxicity 0.000 abstract description 2
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 9
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 6
- 229940043276 diisopropanolamine Drugs 0.000 description 6
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000013460 sweaty Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OTJFQRMIRKXXRS-UHFFFAOYSA-N (hydroxymethylamino)methanol Chemical compound OCNCO OTJFQRMIRKXXRS-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57121853A JPS5913714A (ja) | 1982-07-13 | 1982-07-13 | 外用消炎鎮痛剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS528283A2 CS528283A2 (en) | 1985-07-16 |
| CS241062B2 true CS241062B2 (en) | 1986-03-13 |
Family
ID=14821545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS835282A CS241062B2 (en) | 1982-07-13 | 1983-07-12 | Method of anti-inflammation agent production for local application |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4678666A (OSRAM) |
| EP (1) | EP0101178B2 (OSRAM) |
| JP (1) | JPS5913714A (OSRAM) |
| KR (1) | KR860001801B1 (OSRAM) |
| AR (1) | AR230375A1 (OSRAM) |
| AU (1) | AU543654B2 (OSRAM) |
| CA (1) | CA1206418A (OSRAM) |
| CS (1) | CS241062B2 (OSRAM) |
| DD (1) | DD209972A5 (OSRAM) |
| DE (1) | DE3373270D1 (OSRAM) |
| DK (1) | DK159640C (OSRAM) |
| EG (1) | EG17670A (OSRAM) |
| ES (1) | ES524094A0 (OSRAM) |
| FI (1) | FI78235C (OSRAM) |
| GR (1) | GR78874B (OSRAM) |
| HK (1) | HK85289A (OSRAM) |
| HU (1) | HU187110B (OSRAM) |
| IE (1) | IE54844B1 (OSRAM) |
| IL (1) | IL69207A0 (OSRAM) |
| IN (1) | IN159679B (OSRAM) |
| NO (1) | NO162494C (OSRAM) |
| NZ (1) | NZ204870A (OSRAM) |
| PH (1) | PH18117A (OSRAM) |
| PL (1) | PL147503B1 (OSRAM) |
| PT (1) | PT77016B (OSRAM) |
| SG (1) | SG30489G (OSRAM) |
| ZA (1) | ZA835058B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6168413A (ja) * | 1984-09-10 | 1986-04-08 | Lion Corp | 外用ゲル組成物 |
| IT1196307B (it) * | 1984-10-22 | 1988-11-16 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam monoidrato |
| US4654169A (en) * | 1985-02-06 | 1987-03-31 | Givaudan Corporation | Phenyl-aliphatic oximes as odorants |
| JPS61212516A (ja) * | 1985-03-18 | 1986-09-20 | Toyobo Co Ltd | ピロキシカム軟膏剤 |
| JPH0794394B2 (ja) * | 1986-12-24 | 1995-10-11 | 前田薬品工業株式会社 | 消炎鎮痛外用貼付剤 |
| US5241925A (en) * | 1988-12-27 | 1993-09-07 | Dermamed | Apparatus and techniques for administering veterinary medicaments |
| US5332577A (en) * | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
| US5599768A (en) * | 1989-09-21 | 1997-02-04 | E. I. Du Pont De Nemours And Company | Stabilization of non-aqueous suspensions |
| US4988500A (en) * | 1989-09-29 | 1991-01-29 | The Procter & Gamble Company | Oral compositions |
| US5324521A (en) * | 1989-12-18 | 1994-06-28 | Dermamed | Systems for transdermal administration of medicaments |
| ATE95421T1 (de) * | 1990-04-26 | 1993-10-15 | Sagitta Arzneimittel Gmbh | Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung. |
| FR2679135B1 (fr) * | 1991-07-18 | 1995-05-19 | Europhta Sa Laboratoire | Nouvelles compositions ophtalmiques a adhesivite amelioree et leurs procedes de preparation. |
| US5362758A (en) * | 1992-09-18 | 1994-11-08 | Pfizer Inc. | Ophthalmic piroxicam solution |
| HU209518B (en) * | 1992-12-23 | 1994-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of free of skin damaging effect unguent preparation containing piroxicam |
| US5436241A (en) * | 1994-01-14 | 1995-07-25 | Bristol-Myers Squibb Company | Topical anti-inflammatory compositions containing piroxicam |
| ES2074030B1 (es) * | 1994-01-31 | 1996-02-01 | S A L V A T Lab Sa | Composiciones portadoras, autocalentadoras y aplicables en terapeutica por via topica. |
| US5905092A (en) * | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
| US5807568A (en) * | 1994-12-27 | 1998-09-15 | Mcneil-Ppc, Inc. | Enhanced delivery of topical compositions containing flurbiprofen |
| GB2305603A (en) * | 1995-09-26 | 1997-04-16 | Allied Medical Group | Topical cooling gels for reducing excess body fat |
| RU2114611C1 (ru) * | 1995-12-21 | 1998-07-10 | Валентина Васильевна Малиновская | Мазь |
| RU2141819C1 (ru) * | 1997-07-15 | 1999-11-27 | Пермское научно-производственное объединение "Биомед" | Мазь с интерфероном человеческим лейкоцитарным "интерон" |
| KR100288190B1 (ko) * | 1998-02-09 | 2001-04-16 | 김용규 | 피록시캄 함유 알콜성 하이드로겔 조성물 |
| RU2137469C1 (ru) * | 1998-04-16 | 1999-09-20 | Государственный научный центр лекарственных средств | Противовоспалительное и антимикробное лекарственное средство для местного применения |
| KR100342945B1 (ko) * | 1999-03-09 | 2002-07-02 | 민경윤 | 항진균제의 외용 약제 조성물 및 이의 제조방법 |
| RU2148397C1 (ru) * | 1999-08-18 | 2000-05-10 | Гройсман Валентина Михайловна | Мазь для лечения заболеваний и повреждений кожи |
| IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
| KR100406576B1 (ko) * | 2001-06-23 | 2003-11-20 | 최후균 | 경피투여용 패취제 |
| US20060067958A1 (en) * | 2004-09-24 | 2006-03-30 | Unilab Pharmatech, Ltd. | Pharmaceutical topical gel compositions |
| JP2006188500A (ja) * | 2004-12-08 | 2006-07-20 | Toyama Chem Co Ltd | ピロキシカムを含有する外用液剤 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| KR102319497B1 (ko) * | 2016-03-02 | 2021-11-01 | 노반, 인크. | 염증 치료용 조성물 및 염증 치료 방법 |
| KR20210133821A (ko) | 2020-04-29 | 2021-11-08 | 신신제약 주식회사 | 피록시캄을 함유하는 경피 흡수 제제 |
| JP2024520097A (ja) * | 2021-05-28 | 2024-05-21 | ベタリナリー・ファーマシー・コーポレイション | 水溶性複合組成物およびその方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3541584A (en) | 1968-08-14 | 1970-11-17 | Bendix Corp | Control for fog simulator effects |
| US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
| JPS52156913A (en) * | 1976-06-21 | 1977-12-27 | Toko Yakuhin Kogyo Kk | Production of injectionable medicine |
| JPS5381616A (en) * | 1976-12-27 | 1978-07-19 | Kowa Co | Production of antiinflammatory and anodyne ointment |
| JPS5540604A (en) | 1978-09-14 | 1980-03-22 | Mitsui Toatsu Chem Inc | Improved local topicum |
| US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
-
1982
- 1982-07-13 JP JP57121853A patent/JPS5913714A/ja active Granted
-
1983
- 1983-06-15 IN IN404/DEL/83A patent/IN159679B/en unknown
- 1983-07-07 EP EP83303962A patent/EP0101178B2/en not_active Expired - Lifetime
- 1983-07-07 DE DE8383303962T patent/DE3373270D1/de not_active Expired
- 1983-07-09 EG EG421/83A patent/EG17670A/xx active
- 1983-07-11 PH PH29203A patent/PH18117A/en unknown
- 1983-07-11 IE IE1611/83A patent/IE54844B1/en not_active IP Right Cessation
- 1983-07-11 GR GR71896A patent/GR78874B/el unknown
- 1983-07-11 AR AR293574A patent/AR230375A1/es active
- 1983-07-12 NO NO832529A patent/NO162494C/no not_active IP Right Cessation
- 1983-07-12 DD DD83252997A patent/DD209972A5/de unknown
- 1983-07-12 HU HU832484A patent/HU187110B/hu unknown
- 1983-07-12 CS CS835282A patent/CS241062B2/cs unknown
- 1983-07-12 DK DK320583A patent/DK159640C/da not_active IP Right Cessation
- 1983-07-12 PL PL1983242971A patent/PL147503B1/pl unknown
- 1983-07-12 IL IL69207A patent/IL69207A0/xx not_active IP Right Cessation
- 1983-07-12 PT PT77016A patent/PT77016B/pt unknown
- 1983-07-12 AU AU16767/83A patent/AU543654B2/en not_active Expired
- 1983-07-12 FI FI832536A patent/FI78235C/fi not_active IP Right Cessation
- 1983-07-12 NZ NZ204870A patent/NZ204870A/en unknown
- 1983-07-12 CA CA000432288A patent/CA1206418A/en not_active Expired
- 1983-07-12 ZA ZA835058A patent/ZA835058B/xx unknown
- 1983-07-12 KR KR1019830003173A patent/KR860001801B1/ko not_active Expired
- 1983-07-13 ES ES524094A patent/ES524094A0/es active Granted
-
1986
- 1986-08-14 US US06/896,370 patent/US4678666A/en not_active Expired - Lifetime
-
1989
- 1989-05-11 SG SG304/89A patent/SG30489G/en unknown
- 1989-10-26 HK HK852/89A patent/HK85289A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS241062B2 (en) | Method of anti-inflammation agent production for local application | |
| US4316887A (en) | Composition for topical application and method for preparing the same | |
| US4670254A (en) | Gel preparations for topical application of diclofenac sodium | |
| PT503988E (pt) | Composicoes para o tratamento de onicomicoses | |
| HUP0201145A2 (hu) | Prosztaglandin E1 leadására szolgáló helyileg adagolandó készítmények | |
| EP0007595B1 (en) | Preparations of clotrimazole and process for preparing same | |
| KR100413143B1 (ko) | 국소용 니메설라이드 겔 시스템 | |
| JPH10152433A (ja) | 被膜形成性抗真菌剤組成物 | |
| CN114206387A (zh) | 以抗真菌药作为有效成分的药物组合物 | |
| PL172663B1 (pl) | hydroksyetoksy)metylo]guanine (acyklowir) lub sól albo ester tego zwiazku PL PL PL PL PL PL PL PL | |
| HU225044B1 (en) | Nimesulide containing topical pharmaceutical compositions and process for their preparation | |
| WO2003105841A1 (ja) | 抗真菌医薬組成物 | |
| JPH07557B2 (ja) | 皮膚炎に対する治療用組成物 | |
| JPS6218526B2 (OSRAM) | ||
| WO2016157112A1 (en) | Topical spray compositions of mometasone furoate | |
| RU2140258C1 (ru) | Гидрофильная фармацевтическая композиция, обладающая противовоспалительным действием | |
| JP2548686B2 (ja) | 外用薬剤組成物 | |
| JPH07106982B2 (ja) | 外用薬剤組成物 | |
| RU2799329C1 (ru) | Фармацевтическая композиция, содержащая противогрибковое средство в качестве активного ингредиента | |
| EA018384B1 (ru) | Композиция дигидрата 3-(2,2,2-триметилгидразиниум) пропионата для наружного местного применения | |
| JPH0242812B2 (OSRAM) | ||
| SK141993A3 (en) | Treatmental unguent without irritative reaction for skin and the method of its preparation | |
| JPS60166617A (ja) | 塩酸ニカルジピン外用剤 |